Moderna Q4 revenue $678M (-30% YoY); net loss $(826)M; FY2025 net loss $(2.8)B

Moderna, Inc.

2025-FY EPS reported -$7.26 revenue$1,944,000,000

Q4 2025 revenue $678M (-30% YoY); GAAP net loss $(826)M ($(2.11) EPS).
Full-year 2025 revenue $1.9B (-40% YoY); net loss $(2.8)B ($(7.26) EPS).
2026 guidance: up to 10% revenue growth; R&D ~$3.0B; year-end cash $5.5-6.0B.
U.S. FDA issued Refusal-to-File for seasonal flu vaccine (mRNA-1010); Moderna requested Type A meeting.
Norovirus Phase 3 fully enrolled; intismeran autogene Phase 2 bladder cancer fully enrolled; data readouts expected 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.